share_log

Chemomab Therapeutics Q2 EPS $(0.03) Beats $(0.25) Estimate

Chemomab Therapeutics Q2 EPS $(0.03) Beats $(0.25) Estimate

Chemomab Treateutics第二季度每股收益$(0.03)超過$(0.25)預期
Benzinga Real-time News ·  2022/08/12 06:04

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.25) by 88 percent. This is a 88.46 percent increase over losses of $(0.26) per share from the same period last year.

化學單抗治療公司(納斯達克代碼:CMMB)公佈季度虧損為每股0.03美元,比分析師普遍預期的0.25美元高出88%。這比去年同期每股虧損0.26美元增加了88.46%。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論